Northeast Financial Consultants Inc Harmony Biosciences Holdings, Inc. Transaction History

Northeast Financial Consultants Inc

  • $2.25 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
SELL
$45.4 - $60.91 $204,300 - $274,095
-4,500 Reduced 49.29%
4,629 $255,000
Q3 2022

Nov 15, 2022
SELL
$42.06 - $55.45 $378,540 - $499,050
-9,000 Reduced 49.64%
9,129 $404,000
Q4 2021

Feb 11, 2022
SELL
$34.09 - $43.91 $613,620 - $790,379
-18,000 Reduced 49.82%
18,129 $773,000
Q3 2021

Nov 15, 2021
BUY
$25.68 - $38.61 $19,157 - $28,803
746 Added 2.11%
36,129 $1.39 Million
Q2 2021

Aug 16, 2021
BUY
$25.96 - $33.44 $918,542 - $1.18 Million
35,383 New
35,383 $999,000

Others Institutions Holding HRMY

# of Institutions
243
Shares Held
45.2M
Call Options Held
108K
Put Options Held
49.2K
View Full List

About Harmony Biosciences Holdings, Inc.

HRMY Quotes by TradingView
  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $1.94B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Northeast Financial Consultants Inc Portfolio

Follow Northeast Financial Consultants Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

News

Stay updated on Northeast Financial Consultants Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email